News - Neurological, Cardio-vascular

Filter

Popular Filters

1 to 25 of 30 results

Pharmacovigilance Risk Assessment Committee April meeting highlights

Pharmacovigilance Risk Assessment Committee April meeting highlights

11-04-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) gave a recommendation…

Cardio-vascularEuropeMen's HealthNeurologicalPharmaceuticalRegulationRespiratory and Pulmonary

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California

17-02-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

Radiopharmaceuticals market to hit a value of $7.9 billion by 2018

21-08-2013

The radiopharmaceuticals market has been forecast to exceed a value of $7.9 billion by 2018, driven by…

Cardio-vascularGlobalMarkets & MarketingNeurologicalOncologyPharmaceutical

Generic versions of Trilipix debut in USA; Mylan sued by UCB

16-07-2013

Impax Laboratories (Nasdaq: IPXL) today announced yesterday (July 15) that it is commencing shipment…

AbbVieCardio-vascularGenericsImpax LaboratoriesLegalMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaPatentsTripilixUCBVimpat

Abcam in deal with Pfizer to supply compounds to researchers

12-06-2013

UK-based Abcam (AIM: ABC), a producer and distributor of protein research tools, has entered into a license…

AbcamCardio-vascularLicensingNeurologicalOncologyPfizerPharmaceuticalResearch

Impax launches authorized generic of Zomig, as Mylan debuts copy of Tricor in USA

20-05-2013

US drugmaker Impax Laboratories (Nasdaq: IPXL) says that its generics division, Global Pharmaceuticals,…

AbbVieAstraZenecaCardio-vascularGenericsImpax LaboratoriesMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaTricorZomig

EMA Pharmacovigilance committee calls for Tredaptive suspension; contraceptives update

13-01-2013

At meetings held last week, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee…

Cardio-vascularEuropeMerck & CoNeurologicalPharmaceuticalRegulationReproductivetetrazepamTredaptive

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

NeuroVive and Sihuan Pharma to develop and commercialize CicloMulsion and NeuroSTAT in China

21-11-2012

Swedish mitochondrial medicine firm NeuroVive has announced a collaboration with China's Sihuan Pharmaceutical…

Asia-PacificCardio-vascularCicloMulsionLicensingNeurologicalNeuroSTATNeuroVivePharmaceuticalSihuan Pharmaceutical

Germany invalidates Seroquel patent; Merck drops combo diabetes drug development

14-11-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany…

AstraZenecaatorvastatinCardio-vascularDiabetesJanuviaMerck & CoMK-0431ENeurologicalPatentsPharmaceuticalResearchSeroquel XR

Mylan debuts first generic Diovan HCT and Antivert copy in USA

23-09-2012

US generic drugmaker Mylan (Nasdaq: MYL) last Friday received final approval from the US Food and Drug…

AntivertCardio-vascularDiovan HCTGenericsMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartisPfizerRegulation

Wockhardt generic versions of Pfizer's Geodon and AstraZeneca's Plendil OKed by FDA

23-08-2012

Wockhardt generic versions of Pfizer's Geodon and AstraZeneca's Plendil OKed by FDA

AstraZenecaCardio-vascularGenericsGeodonMarkets & MarketingNeurologicalNorth AmericaPfizerPlendilRegulationWockhardt

EMA calls for curbs on trimetazidine-containing and tolperisone medicines

24-06-2012

The European Medicines Agency on Friday recommended restricting the use of trimetazidine-containing medicines…

Cardio-vascularEuropeNeurologicalPharmaceuticalRegulationServiertolperisonetrimetazidineVestrel

Novartis makes Tekturna label change, updates on Gilenya and stops alisporivir trial

20-04-2012

In a day of mixed news for the Swiss drug major, Novartis (NOVN: VX) said yesterday that it has updated…

alisporivirAnti-viralsCardio-vascularGilenyaNeurologicalNovartisPharmaceuticalRegulationResearchTekturna

Mylan debuts Lescol copy; Impax challenges Gralise patent

16-04-2012

US generic drug major Mylan (Nasdaq: MYL) revealed last Friday that it has begun shipping its generic…

Cardio-vascularDepomedGenericsGraliseImpax LaboratoriesLescolMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartisPatentsRegulation

RegeneRx explores strategic options

02-02-2012

US biotech firm RegeneRx Biopharmaceuticals. (OTC Bulletin Board: RGRX) revealed yesterday that it has…

BiotechnologyCardio-vascularDermatologicalsLicensingNeurologicalOphthalmicsRegeneRx

Watson settles over Exalgo; gets favorable news on enoxaparin

29-01-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) says that its subsidiary, Watson Laboratories,…

Cardio-vascularEnoxaparin Sodium InjectionExalgoGenericsLegalLovenoxMallinckrodtMomenta PharmaceuticalsNeurologicalNorth AmericaSanofiWatson Pharmaceuticals

Sobi buys rights to novel neonatology treatment

16-01-2012

Stockholm-based Swedish Orphan Biovitrum (STO: SOBI) has signed a global licensing agreement with the…

BumetanideCardio-vascularLicensingNeurologicalOnly for Children PharmaceuticalsPharmaceuticalSwedish Orphan Biovitrum

FDA strengthens warnings on Sanofi’s Multaq; Aubagio disappoints

20-12-2011

The US Food and Drug Administration (FDA) has completed a safety review of French drug major Sanofi’s…

AubagioCardio-vascularMultaqNeurologicalPharmaceuticalRegulationResearchSanofi

1 to 25 of 30 results

Back to top